Happenings

New AL-ISS Model Validated for Prognosis in AL Amyloidosis
Feb 26, 2026
New AL-ISS Model Validated for Prognosis in AL Amyloidosis
A new system for staging of systemic AL amyloidosis, the AL International Staging System (AL-ISS) was developed and externally validated in a study with findings…
Read more
Mixed primary progressive aphasia and alcohol use disorder: a case of detailed clinical phenotyping outperforming molecular imaging
Feb 19, 2026
Mixed primary progressive aphasia and alcohol use disorder: a case of detailed clinical phenotyping outperforming molecular imaging
ABSTRACTPrimary progressive aphasia (PPA) refers to a group of clinically and pathologically heterogeneous syndromes characterized by progressive and relatively…
Read more
Attruby slows disease progression across ATTR-CM subgroups: Trial data
Feb 19, 2026
Attruby slows disease progression across ATTR-CM subgroups: Trial data
Attruby (acoramidis) slows disease progression and significantly reduces death and cardiovascular-related hospitalizations in adults with hereditary or wild-type…
Read more
Sex-specific early cognitive changes are linked to global and pathway-specific genetic risk for Alzheimer's disease in at-risk individuals
Feb 18, 2026
Sex-specific early cognitive changes are linked to global and pathway-specific genetic risk for Alzheimer's disease in at-risk individuals
Biology of sex differencesBiol Sex Differ. 2026 Feb 17. doi: 10.1186/s13293-025-00800-w. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is a progressive…
Read more
Amyloidosis in Carpal Tunnel Syndrome and 1-Year Cardiovascular and Renal Outcomes: A Propensity Score-Matched Cohort Study
Feb 17, 2026
Amyloidosis in Carpal Tunnel Syndrome and 1-Year Cardiovascular and Renal Outcomes: A Propensity Score-Matched Cohort Study
AbstractBackground: Carpal tunnel syndrome (CTS) has been recognized as a potential early manifestation of systemic amyloidosis; however, its prognostic…
Read more
Plasma ATN biomarkers across the alzheimer's disease continuum in a Chilean community- and clinic-based cohort
Feb 16, 2026
Plasma ATN biomarkers across the alzheimer's disease continuum in a Chilean community- and clinic-based cohort
Alzheimers Res Ther. 2026 Feb 14. doi: 10.1186/s13195-026-01974-0. Online ahead of print.ABSTRACTBACKGROUND: Plasma biomarkers have emerged as robust indicators of…
Read more
Hologic Gains FDA Clearance for Aptima® HPV Assay as Primary Screening Tool; ZOLL Zenix Monitor/Defibrillator Achieves MDR Approval; Labcorp Unveils FDA-Cleared Blood Test for Alzheimer’s Screening; P&F SecureD EU MDR CE Mark Approval for the TricValve® S
Feb 12, 2026
Hologic Gains FDA Clearance for Aptima® HPV Assay as Primary Screening Tool; ZOLL Zenix Monitor/Defibrillator Achieves MDR Approval; Labcorp Unveils FDA-Cleared Blood Test for Alzheimer’s Screening; P&F SecureD EU MDR CE Mark Approval for the TricValve® S
Hologic Received FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio On February 04, 2026, Hologic, Inc. announced…
Read more
Could a Rare Heart Condition Be Hidden behind Heart Failure Diagnoses? ATTR-CM Emerges as Underrecognized Threat
Feb 06, 2026
Could a Rare Heart Condition Be Hidden behind Heart Failure Diagnoses? ATTR-CM Emerges as Underrecognized Threat
A rare and potentially fatal form of heart disease known as transthyretin amyloid cardiomyopathy, or ATTR-CM, is increasingly drawing clinical attention as…
Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Feb 02, 2026
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs.  Approximately 3,260…
Read more
Nuclear imaging in transthyretin amyloid cardiomyopathy
Feb 02, 2026
Nuclear imaging in transthyretin amyloid cardiomyopathy
This thesis of Hendrea Tingen investigates how nuclear imaging can improve the diagnosis, monitoring of disease progression, and evaluation of treatment response in…
Read more
Subscribe to